Gotowa bibliografia na temat „Thrombotic complications”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Thrombotic complications”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Thrombotic complications"
Lim, Sunghee, Ji Yoon Lee, Seok Jin Kim i Won Seog Kim. "The International Prognostic Index Is a Better Predictor of Thrombotic Complications Than the Khorana Score for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Results of a Single Center Prospective Cohort Study". Blood 120, nr 21 (16.11.2012): 5095. http://dx.doi.org/10.1182/blood.v120.21.5095.5095.
Pełny tekst źródłaMakatsaria, Alexander Davidovich, Svetlana Vladimirovna Akinshina, Viktoriya Omarovna Bitsadze i Margarita Darchievna Andreeva. "Severe obstetric complications as a manifestation of thrombotic microangiopathy". Journal of obstetrics and women's diseases 64, nr 5 (15.12.2015): 6–15. http://dx.doi.org/10.17816/jowd6456-15.
Pełny tekst źródłaOgurkova, O. N., M. A. Dragunova, T. E. Suslova, Yu G. Lugacheva i R. E. Batalov. "Evaluation of the CD40 receptor-ligand system in the patients with atrial fibrillation of non-valvular genesis". Medical Immunology (Russia) 24, nr 6 (8.12.2022): 1255–64. http://dx.doi.org/10.15789/1563-0625-eot-2532.
Pełny tekst źródłaHaman, Luděk, Petr Pařízek, Radovan Malý, Jiří Duda i Jaroslav Malý. "Analysis of Thrombotic Complications After Catheter Ablation". Acta Medica (Hradec Kralove, Czech Republic) 49, nr 1 (2006): 47–50. http://dx.doi.org/10.14712/18059694.2017.109.
Pełny tekst źródłaJenner, William J., Rahim Kanji, Saeed Mirsadraee, Ying X. Gue, Susanna Price, Sanjay Prasad i Diana A. Gorog. "Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review". Journal of Thrombosis and Thrombolysis 51, nr 3 (14.02.2021): 595–607. http://dx.doi.org/10.1007/s11239-021-02394-7.
Pełny tekst źródłaSousa Nanji, Liliana, André Torres Cardoso, João Costa i António Vaz-Carneiro. "Analysis of the Cochrane Review: Thrombolysis for Acute Deep Vein Thrombosis. Cochrane Database Syst Rev. 2014,1: CD002783." Acta Médica Portuguesa 28, nr 1 (27.02.2015): 12. http://dx.doi.org/10.20344/amp.6286.
Pełny tekst źródłaCapecchi, Marco, Alessandro Ciavarella, Andrea Artoni, Maria Abbattista i Ida Martinelli. "Thrombotic Complications in Patients with Immune-Mediated Hemolysis". Journal of Clinical Medicine 10, nr 8 (18.04.2021): 1764. http://dx.doi.org/10.3390/jcm10081764.
Pełny tekst źródłaMcFadyen, James D., Hannah Stevens i Karlheinz Peter. "The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications". Circulation Research 127, nr 4 (31.07.2020): 571–87. http://dx.doi.org/10.1161/circresaha.120.317447.
Pełny tekst źródłaRoutledge, David JM, Joanna Tomlins, Adrian Bloor, Kaz Mamat, Michael Dennis, Jim Cavet, Tim Somervaille, Sven Armin Sommerfeld i Samar Kulkarni. "Incidence of Thrombotic Complications with Use of Peg-Asparginase in Treatment for Acute Lymphoblastic Leukemia (ALL) in Adults and Young Adolescent Patients". Blood 126, nr 23 (3.12.2015): 4864. http://dx.doi.org/10.1182/blood.v126.23.4864.4864.
Pełny tekst źródłaBorota, A. V., A. A. Borota i E. V. Onishchenko. "Thrombotic Complications in Inflammatory Bowel Disease". Russian Journal of Gastroenterology, Hepatology, Coloproctology 29, nr 2 (16.05.2019): 23–26. http://dx.doi.org/10.22416/1382-4376-2019-29-2-23-26.
Pełny tekst źródłaRozprawy doktorskie na temat "Thrombotic complications"
Tardy-Poncet, Brigitte. "Potential roles of TFPI in both thrombotic and hemorrhagic diseases". Thesis, Saint-Etienne, 2012. http://www.theses.fr/2012STET007T/document.
Pełny tekst źródłaTFPI is a multivalent Kunitz-type proteinase inhibitor that directly inhibits FXa and produces FXa-dependent feedback inhibition of the FVIIa–TF complex. It was recently demonstrated that Protein S (PS) plays the role of TFPI cofactor by enhancing the TFPI inhibition of factor Xa in vivo. Approximately 80% of plasma TFPI circulates as a complex with plasma lipoproteins, about 5–20% circulating as free TFPI. Under quiescent conditions, approximately 50–80% of intravascular TFPI is stored in association with the endothelium. Full-length TFPI α carried in platelets constitutes 8-10% of the total amount of TFPI in the blood, corresponding to a quantity comparable to that of soluble full-length TFPI α in the plasma. We searched for resistance to TFPI activity in patients who presented idiopathic venous thrombosis at a young age. Plasma sensitivity to TFPI was evaluated on the basis of diluted prothrombin time (dPT) measured in patients and in control plasma in the presence (W) and absence (Wo) of exogenous TFPI. At the same time, dPT was measured on a reference plasma to establish a normalized ratio termed TFPI NR and defined as (dPT wTFPI/ dPT Wo TFPI) patient or control / (dPT wTFPI/ dPT Wo TFPI) reference plasma. In an initial study, we found that TFPI resistance could be considered as a new coagulation abnormality that could be related to unexplained thrombosis. In a second study, we failed to demonstrate a role of TFPI resistance in patients with venous thrombosis, abnormal TFPI NR being more likely related to the non-respect of preanalytical conditions rather than to an inherited trait. However, in another study, we showed that inherited or acquired PS deficiency was responsible for a TFPI resistance, providing an ex vivo demonstration that PS is the cofactor of TFPI activity. We showed that this TFPI resistance existed throughout pregnancy and that it disappeared when PS returned to normal values after delivery. We evaluated this TFPI resistance as a possible marker of the risk of a gestational vascular complication (GVC) in 72 patients at risk of developing a GVC. TFPI NR did not differ between GVC+ patients (n =15) and GVC– patients (n = 57). High levels of Lipoprotein(a) (Lp(a) have been shown to be an independent risk factor for cardiovascular disease, lowering of these levels not being achievable by any treatment except possibly aspirin. An in vitro study showed that TFPI activity could be inhibited by Lp(a). We did not confirm this TFPI inhibition in vivo in 20 obese patients with coronary insufficiency who had either normal Lp(a) levels (≤ 0.3 g/L; n = 15) or high Lp(a) levels (≥ 0.3 g/L; n = 5) . Moreover, we found no effect of aspirin treatment on Lp(a) whatever the initial level of Lp(a). Haemophilia B patients bleed less than haemophilia A patients. We showed that this difference in bleeding profile could be explained by lower free TFPI levels in haemophilia B patients compared to haemophilia A patients. In an ongoing study, we showed that in haemophilia A patients there was a strong correlation between the different parameters of thrombin generation (TG) and free TFPI. We also showed, in a TG assay performed in platelet-rich plasma (PRP) with a low TF concentration, that LT was sensitive to free TFPI levels whatever the type of haemophilia and whatever theseverity of the disease. We demonstrated that blocking TFPI by an anti-TFPI Antibody (Ab) allows complete correction of the TG profile in PRP. We showed that it is of major importance to perform a TG assay in PRP in order to evaluate the efficacy of anti-TFPI Ab in correcting TG parameters in haemophilia patients
Moussa, Mouhamed Djahoum. "Déterminants cliniques, physiopathologiques et pronostics associés aux complications liées à l’hémostase au cours des assistances circulatoires de courte durée à pompe centrifuge". Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS055.
Pełny tekst źródłaThe purpose of this dissertation is to characterize hemostasis-related complications in patients supported by peripheral VA-ECMO to improve their prevention and to optimize the antithrombotic therapeutic approaches in use. In a first study, we qualitatively and quantitatively described the composition of thrombi collected from the VA-ECMO circuits. We observed that these thrombi are mainly made of VWF, fibrin and in a lesser proportion of platelets and RBCs. Our quantitative approach also allowed us to demonstrate the presence of NETs while there was no active septic, confirming the possibility of aseptic NETosis under VA-ECMO. By hierarchical cluster analysis, we identified 2 types of thrombi, each of which may be related to a different mechanism of formation. In this study, the location of thrombi on the VA-ECMO circuit did not impact their compositions, highlighting the heterogeneity of thrombi formed within VA-ECMO and the multifactorial mechanisms that support thrombosis in this setting. In a second study, we compared the performance of surface coatings on VA-ECMO circuits to reduce thrombinoformation and its clinical consequences. Two of the most used coatings in daily practice were compared: the phosphorylcholin-based coating and the polysaccharide-albumin-based coating. We observed a higher rate of thrombotic complications in the phosphorylcholin group without any excess bleeding events or mortality in either group. In addition, compared with thrombi from phosphorylcholin-coated circuit junctions, those from polysaccharide-albumin-coated circuits were poorer in VWF. Our work suggests that the level of anticoagulation should be modulated according to the type of coating of the ECMO circuit.The aim of our third study was to identify the most relevant bleeding events that may guide clinical decision-making for more aggressive clinical management and a greater investment in research. To this end, we compared the association between 3 bleeding classifications with 28-day mortality. The ELSO definition already in use and the BARC classification classes ≥ type 2 were associated with 28-day mortality and thus retained as definitions of major bleeding. Laboratory parameters that are predictors major bleeding according to the ELSO definition were decreased fibrinogen, platelet count, and hemoglobin at cannulations. Body mass index and postcardiotomy etiology were also predictive of ELSO major bleeding. In an additional work related to the topic of the thesis, we studied two of the most used laboratory tests for the monitoring of systemic heparin during VA-ECMO, the APTT and the Anti-Xa activity, to identify the most relevant. First, we studied the relationship between these two tests and then analyzed in a second objective the impact of biological influencing factors on this relationship. Next, we determined their associations with thrombotic and hemorrhagic complications. Although linearly associated, the rate of discordance between their measurements was 39 % for an Anti-Xa reference range of 0.3 - 0.7 IU/mL. Neither APTT nor Anti-Xa was associated with thrombotic or bleeding complications. Taken together, our results highlight the heterogeneity of thrombi from peripheral VA-ECMO, the involvement of numerous causal factors that underline thrombotic and hemorrhagic complications, both not predictable by routine tests. Finally, our work underscored the need for new approaches in thrombotic or hemorrhagic complications management with targets set at an individual level considering both patient and ECMO circuit characteristics
Lapidus, Lasse. "Thromboembolism following orthopaedic surgery : outcome and diagnostic procedures after prophylaxis in lower limb injuries /". Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-111-1/.
Pełny tekst źródłaSmith, Sarah Faith. "Influences on the incidence of clinical deep vein thrombosis and pulmonary embolism in a prospectively collated population of 21,000 neurosurgical inpatients". Thesis, The University of Sydney, 2001. http://hdl.handle.net/2123/818.
Pełny tekst źródłaSmith, Sarah Faith. "Influences on the incidence of clinical deep vein thrombosis and pulmonary embolism in a prospectively collated population of 21,000 neurosurgical inpatients". University of Sydney. Public Health and Community Medicine, 2001. http://hdl.handle.net/2123/818.
Pełny tekst źródłaZiaziaris, William Andrew. "Pediatric Liver Transplantation: Improvement in Outcomes". Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/16265.
Pełny tekst źródłaMatielo, Marcelo Fernando. "Incidência de trombose venosa profunda pós-operatória no membro amputado de pacientes com doença arterial oclusiva periférica". Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5132/tde-29012009-165529/.
Pełny tekst źródłaIntroduction: Patients undergoing amputation of the lower limb due to Peripheral Arterial Disease (PAD) are at risk for developing Deep Venous Thrombosis (DVT). There are few studies in the research literature on the incidence of DVT during the early postoperative period and the risk factors for the development of DVT in the amputation stump. Objective: The goal of this prospective study was to evaluate the incidence of deep venous thrombosis during the first 35 postoperative days in patients who had undergone amputation of the lower extremity due to PAD, and its relation to comorbidities and death. Method: From September 2004 to March 2006, fifty-six patients (29 men, mean age 67.25 years) underwent 62 amputations (36 below knee amputation BKA and 26 above knee amputation- AKA), and echo- Doppler scanning on preoperative, and approximately the seventh and 31st postoperative days. Results: DVT occurred in 16 (25.8%) of the amputated extremities, (10 AKA and 06 BKA). The cumulative incidence in the 35 day postoperative period was 28% (Kaplan-Meier). There was a significant difference in the incidence of DVT between AKA (37.5%) and BKA (21.2%), p = .04. Another DVT risk factor was age equal to or above 70 years (48.9 vs. 16.8%, p= .021). There was one case of symptomatic non-fatal pulmonary embolism in a patient already diagnosed with DVT. There was no relation between other comorbidities and DVT. Venous Thrombosis in the amputation stump did not influence the mortality rate which was 9.7%. Conclusions: The incidence of DVT in the early post-operative period (up to 35 days) was elevated mainly in patients 70 years of age or older and in AKA. Patients with PAD who have recently undergone major amputations should be considered at high risk for DVT, even after hospital discharge.
Oliveira, Samantha Carlos de. "Trombocitopenia induzida por heparina: aspectos clínicos e laboratoriais". Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5146/tde-04112008-155406/.
Pełny tekst źródłaHeparin induced thrombocytopenia (HIT) is an immune-hematologic syndrome mediated by a heparin dependent antibody that causes platelet activation, platelet aggregation, and can be associated with thrombosis and death. HIT occurs in about 1-5% of patients receiving heparin therapy up to 5 days or more. Many factors influence on the frequency of HIT. This is a pioneer Brazilian study to determine the frequency of HIT on patients under heparin therapy, and the relationship of HIT with gender, heparin type and the FcRIIa platelet receptor genotype. 278 patients from the Intensive Care Unit and Cardiac Care Unit at InCor-HCFMUSP treated with Unfractionated Heparin (UFH) and/or Low Molecular Weight Heparin (LMWH) for 5 or more days were studied. Known causes of thrombocytopenia were excluded. Platelet count was monitored pre and post heparin therapy. All selected patients were tested for detection of anti-heparin/PF4 antibody (ID-PaGIA, DiaMed; and Asserachrom®-HPIA, Stago). HIT frequency found was 6 (2,2%) and the frequency of thrombocytopenia (determined by a decrease in the platelet count below 50%, after the introduction of heparin therapy) and positive anti-heparin/PF4 antibody test was 24,3%. Patients gender was not related to TIH, neither to thrombocytopenia nor to the presence of antiheparin/ PF4 antibody. Thrombosis events were more frequent in women than in men. Thrombocytopenia, related to the type of heparin, was more frequent in patients that had used both types of heparin and less frequent in those that used only LMWH. FcRIIa platelet receptor genotype was associated with neither HIT nor with gender. This study has provided the frequency of HIT in a Brazilian patient population under heparin therapy and auxiliary in the HIT diagnosis. The ID-PaGIA (DiaMed) was shown to be the best test to correlate the presence of anti-heparin/PF4 antibody to thrombocytopenia and thrombosis event. The use of both heparin types promotes more thrombocytopenia. New studies are needed to confirm the relationship between heparin type and thrombocytopenia with HIT
Nilsson, Elin, i Linnéa Oskarsson. "Graderade kompressionsstrumpors preventiva effekt för djup ventrombos och posttrombotiskt syndrom". Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-408302.
Pełny tekst źródłaABSTRACT Background: Deep vein thrombosis (DVT) is a serious complication postoperatively and can lead to a life threatening condition for the patient. Graded compression stockings (GCS) are used in many post-operative departments along with other prophylactic measures to prevent the development of DVT. Compression stockings are also used to prevent postthrombotic syndrome (PTS) after a DVT. PTS can develop because the venous valves are damaged by a DVT, as a result, the blood is stored and edema is formed, which leads to poor nutritional and oxygen supply to the tissues. Aim: The aim of the literature study was to investigate whether compression stockings had any effect in preventing DVT postoperatively, and also whether the compression stockings had any effect in preventing PTS after a DVT. Method: Literature study based on 11 RCT studies. Results: GCS without other prophylactic measures was found to have a good effect in avoiding the development of DVT in patients who underwent surgery. However, the use of GCS in combination with other proven prophylaxis was found to have no significant effect in further reducing the onset of DVT. The results regarding the GCS effect to avoid the development of PTS showed no unambiguity. Conclusion: GCS has a preventive effect to avoid the onset of DVT. However, the use of GCS in combination with other prophylaxis does not potentiate the effect of prevention for DVT. The effect of GCS in preventing the onset of PTS is not unambiguous and several studies are needed to see evidence of this.
Galanaud, Jean-Philippe. "Les thromboses veineuses méconnues des membres inferieurs : thromboses veineuses profondes distales et thromboses veineuses superficielles". Thesis, Montpellier 1, 2011. http://www.theses.fr/2011MON1T027.
Pełny tekst źródłaBackground: Though they represent the majority of all lower limbs thromboses, isolated distal deep-vein thrombosis (DVT) (without symptomatic pulmonary embolism (PE)) and isolated superficial vein thrombosis (SVT) (without DVT or PE) have been poorly studied. Their clinical significance and management are under debate.Methods: Data from epidemiological multicenter prospective studies OPTIMEV, POST, RIETEResults and comments: Isolated distal DVT: Distal and proximal DVTs exhibit a different risk factor profile, the latter being more associated with chronic risk factors. Three-month mortality of distal DVT patient is lower than that of proximal DVT ones but is higher than that of controls. This evidences that distal DVT is a clinically significant finding. Differences in population profile and outcomes suggests that the benefit/risk ratio of anticoagulant treatment is not similar. Data from proximal DVT clinical trials should no longer be extrapolated to distal DVT.Isolated SVT: In case of SVT the risk of concomitant DVT is high. A compression ultrasonographic exam should be performed and at least explore the whole deep venous system of the affected limb. Male gender and history of DVT/Pulmonary embolism are independent predicators of recurrence. Some SVT can be safely treated without anticoagulants. On contrary, in patients with cancer or a sapheno-femoral junction involvement, the risk of deep venous recurrence is high even upon full therapeutic dose of anticoagulants
Książki na temat "Thrombotic complications"
Hans, Renck, red. Bleeding and thrombotic disorders in the surgical patient. Norwalk, Conn: Appleton & Lange, 1988.
Znajdź pełny tekst źródłaGilles, Lugassy, red. Thrombosis and cancer. London: Martin Dunitz, 2004.
Znajdź pełny tekst źródłaGreco, Caterina F. Stent thrombosis: Epidemiology, prevention, and management. Hauppauge, N.Y: Nova Science, 2011.
Znajdź pełny tekst źródłaPaidas, Michael J. Hemostasis and thrombosis in obstetrics & gynecology. Chichester, West Sussex, UK: Wiley-Blackwell, 2011.
Znajdź pełny tekst źródłaInternational School of Medical Sciences (22nd 1983 Ettore Majorana Center for Scientific Culture). Advances in hemostasis and thrombosis. New York: Plenum Press, 1985.
Znajdź pełny tekst źródłaValentin, Fuster, i Verstraete M, red. Thrombosis in cardiovascular disorders. Philadelphia: Saunders, 1992.
Znajdź pełny tekst źródłaBodnar, Endre, i Eric G. Butchart. Thrombosis, embolism and bleeding. London: ICR Publ., 1992.
Znajdź pełny tekst źródłaWang, Meng-Jiy. Biomaterials in blood-contacting devices: Complications and solutions. New York: Nova Science Publishers, 2010.
Znajdź pełny tekst źródłaM, Verstraete, Fuster Valentin i Topol Eric J. 1954-, red. Cardiovascular thrombosis: Thrombocardiology and thromboneurology. Wyd. 2. Philadelphia: Lippincott-Raven, 1998.
Znajdź pełny tekst źródła1958-, Greer I. A., Turpie, A. G. G. 1939- i Forbes C. D. 1938-, red. Haemostasis and thrombosis in obstetrics and gynaecology. London: Chapman & Hall Medical, 1992.
Znajdź pełny tekst źródłaCzęści książek na temat "Thrombotic complications"
Shah, Rahul, Bipin N. Savani i Shruti Chaturvedi. "Bleeding and Thrombotic Complications". W The EBMT Handbook, 355–63. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_40.
Pełny tekst źródłaChaturvedi, Shruti, Binsah George i Bipin N. Savani. "Bleeding and Thrombotic Complications". W The EBMT Handbook, 301–6. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02278-5_40.
Pełny tekst źródłaPenner, John. "Leukemia: Hemorrhagic and Thrombotic Complications". W Biology and Therapy of Acute Leukemia, 245–59. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2609-0_17.
Pełny tekst źródłaDuléry, Rémy, Martin Schmidt-Hieber i Basil Sharrack. "Neurological Complications". W The EBMT Handbook, 481–87. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_53.
Pełny tekst źródłaTriozzi, Jefferson L., i Saed Shawar. "Recurrent Thrombotic Microangiopathy in a Kidney Transplant Recipient". W Complications in Kidney Transplantation, 255–64. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-13569-9_41.
Pełny tekst źródłaSrivastava, Swati, Iti Garg, Lilly Ganju, Rajeev Varshney i Bhuvnesh Kumar. "Thrombotic Complications in Women: Risks and Prevention". W Biomedical Translational Research, 451–63. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-8845-4_22.
Pełny tekst źródłaLawrence, Peter F., Juan Carlos Jimenez i Kellie R. Brown. "Management of thrombotic complications of endovenous ablations". W Handbook of Venous and Lymphatic Disorders, 479–84. Wyd. 5. Boca Raton: CRC Press, 2024. http://dx.doi.org/10.1201/9781003328971-52.
Pełny tekst źródłaRollo, Johnathon C., i Juan Carlos Jimenez. "Thrombotic Complications Following Treatment of Peripheral Varicose Veins". W Contemporary Management of Acute and Chronic Venous Disease, 96–107. Boca Raton: CRC Press, 2024. http://dx.doi.org/10.1201/9781003316626-13.
Pełny tekst źródłaWallhult, Elisabeth, Michelle Kenyon i Barry Quinn. "Early and Acute Complications and the Principles of HSCT Nursing Care". W The European Blood and Marrow Transplantation Textbook for Nurses, 185–216. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23394-4_10.
Pełny tekst źródłaPetrolla, Amber A., Hillard M. Lazarus i Alvin H. Schmaier. "Unique Thrombotic and Hemostatic Complications Associated with Allogeneic Hematopoietic Stem Cell Transplantation". W Allogeneic Stem Cell Transplantation, 695–715. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-478-0_39.
Pełny tekst źródłaStreszczenia konferencji na temat "Thrombotic complications"
Vasil'ceva, O. YA, i K. N. Vitt. "Diabetes mellitus and thrombotic complications". W Scientific dialogue: Medical issues. ЦНК МОАН, 2019. http://dx.doi.org/10.18411/spc-15-05-2019-07.
Pełny tekst źródłaIvanov, A. A., A. I. ZHdanov, M. S. SHevelin i A. S. Brezhnev. "Analytical assessment of thrombotic and non-thrombotic complications after surgical treatment of abdominal aortic aneurysms". W Scientific achievements of the third millennium. L-Journal, 2020. http://dx.doi.org/10.18411/scienceconf-09-2020-01.
Pełny tekst źródłaYan, Li, Rajeev Kumar Nallamothu i Dan Rafiroiu. "Thrombotic complications of mechanical heart valves: An experimental and theoretical study". W 2013 8th International Symposium on Advanced Topics in Electrical Engineering (ATEE). IEEE, 2013. http://dx.doi.org/10.1109/atee.2013.6563435.
Pełny tekst źródłaSchwartz, R., E. Kavanagh, K. Bauer, R. Rosenberg, J. Ballard, J. Latino, V. Strother, M. Mosesson, W. Haire i M. DeLeo. "ANTITHROMBIN III CONCENTRATE (AT-III) FOR PROPHYLAXIS ANDTREATMENT OF CONGENITAL AND ACQUIREDAT-III DEFCIENCY". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643678.
Pełny tekst źródłaIvanov, A. A., A. I. ZHdanov, M. S. SHevelin i A. S. Brezhnev. "Optimized postoperative prevention program thrombotic complications during intervention for abdominal aneurysm aortic department". W General question of world science. "Science of Russia", 2020. http://dx.doi.org/10.18411/gq-31-07-2020-05.
Pełny tekst źródłaKontopoulou-Griva, Ir, J. Spiliotopoulou, L. Digenopoulou i J. Georgopoulos. "THE THROMBOTIC COMPLICATIONS OF TWO GROUPS OF PATIENTS WITH DIFFERENT INR THERAPEUTIC RANGES. THE NECESSITY OF INTENSE ORAL ANTICOAGULANT TREATMENT". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643263.
Pełny tekst źródłaKoutts, K., i T. Exner. "HIGH INCIDENCE OF CARDIOLIPIN-BINDING ANTIBODIES IN PATIENTS TAKING ORAL ANTICOAGULANTS". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644239.
Pełny tekst źródłaLang, L., G. Cattaneo, F. Popov, T. Krüger, C. Salewski, A. Nemeth, H. P. Wendel, S. Krajewski i C. Schlensak. "Nitrated Oleic Acid Coating of Nitinol Grafts to Diminish Stent-Angioplasty-Associated Thrombotic Complications". W 48th Annual Meeting German Society for Thoracic, Cardiac, and Vascular Surgery. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1678977.
Pełny tekst źródłaBroekmans, A. W., F. J. M. der Meer i K. Briët. "TREATMENT OF CONGENITAL THROMBOTIC SYNDROMES". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643718.
Pełny tekst źródłaSheriff, Jawaad, Gaurav Girdhar, Sheela George, Wei-Che Chiu, Bryan E. Lynch, Jolyon Jesty, Marvin J. Slepian i Danny Bluestein. "In Vitro Evaluation of Shear-Induced Platelet Activation in the MicroMed DeBakey Ventricular Assist Device With Antiplatelet Therapy". W ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14088.
Pełny tekst źródłaRaporty organizacyjne na temat "Thrombotic complications"
Ding, Yukang, Xixia Chen i Yongpeng Ge. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, wrzesień 2022. http://dx.doi.org/10.37766/inplasy2022.9.0084.
Pełny tekst źródłaSaldanha, Ian J., Wangnan Cao, Justin M. Broyles, Gaelen P. Adam, Monika Reddy Bhuma, Shivani Mehta, Laura S. Dominici, Andrea L. Pusic i Ethan M. Balk. Breast Reconstruction After Mastectomy: A Systematic Review and Meta-Analysis. Agency for Healthcare Research and Quality (AHRQ), lipiec 2021. http://dx.doi.org/10.23970/ahrqepccer245.
Pełny tekst źródłaThrombolysis may reduce complications of deep vein thrombosis. National Institute for Health Research, kwiecień 2017. http://dx.doi.org/10.3310/signal-000409.
Pełny tekst źródła